PhRMA has brought in a top clinical research expert — and senior FDA vet — to help guide its lobbying work in Washington, DC.
Richard Moscicki is jumping from his post as deputy director for science operations at CDER right over to a new role as chief medical officer at PhRMA, which has been doing its best to spotlight the industry’s multibillion-dollar investment in drug R&D as it seeks a helpful stance from the federal government on a score of key issues.
After an internal review that led the group to cut ties with companies that had a less-than-stellar track record in investing in R&D, Moscicki will bring an insider’s knowledge of the agency to his new role leading science and regulatory advocacy efforts. He’s also a widely recognized clinical trial expert in his own right, a rep that he built in the Boston area as clinical trial chief and CMO at Genzyme under the late Henri Termeer and then under Sanofi’s guiding hand.
Moscicki spent 34 years on the staff at Mass General and on the faculty at Harvard Med after getting his medical degree at Northwestern.
Ironically, new FDA Commissioner Scott Gottlieb applauded Moscicki’s arrival at the FDA in 2013 — after 21 years at Genzyme — as an example of the badly needed industry expertise the FDA was in short supply of.
Four years ago, he wrote for Forbes: “Today’s announcement gives the agency substantial, practical experience at the top.”
And today’s announcement gives PhRMA the same.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription